Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187

Regulatory Peptides

Volumn 137, Issue 3, 2006, Pages 121-127

  Gedulin, Bronislava R ^a   Jodka, Carolyn M ^a   Herrmann, Kathrin ^a   Young, Andrew A ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

AC187; Gastric emptying; Glucagon

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VASCULOTROPIN;

ARTICLE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMYLOID; ANIMALS; BLOOD GLUCOSE; GASTRIC EMPTYING; GLUCAGON; HOMEOSTASIS; MALE; OBESITY; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PEPTIDE;

EID: 33751563702     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.06.004     Document Type: Article

References (53)

1. Cooper G.J.S., Willis A.C., Clark A., Turner R.C., Sim R.B., and Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84 (1987) 8628-8632
2. Ogawa A., Harris V., McCorkle S.K., Unger R.H., and Luskey K.L. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 85 (1990) 973-976
3. Young A.A. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes 4 (1997) 282-290
4. Christopoulos G., Perry K.J., Morfis M., Tilakaratne N., Gao Y., Fraser N.J., Main M.J., Foord S.M., and Sexton P.M. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56 (1999) 235-242
5. Muff R., Bühlmann N., Fischer J.A., and Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 140 (1999) 2924-2927
6. Beaumont K., Kenney M.A., Young A.A., and Rink T.J. High affinity amylin binding sites in rat brain. Mol Pharmacol 44 (1993) 493-497
7. Young A.A., Gedulin B., Vine W., Percy A., and Rink T.J. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38 (1995) 642-648
8. Kong M.F., King P., Macdonald I.A., Stubbs T.A., Perkins A.C., Blackshaw P.E., Moyses C., and Tattersall R.B. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40 (1997) 82-88
9. Samsom M., Szarka L.A., Camilleri M., Vella A., Zinsmeister A.R., and Rizza R.A. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gasterointest Liver Physiol 278 (2000) G946-G951
10. Gedulin B.R., Rink T.J., and Young A.A. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46 (1997) 67-70
11. Fineman M., Weyer C., Maggs D.G., Strobel S., and Kolterman O.G. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 34 (2002) 504-508
12. Fineman M.S., Koda J.E., Shen L.Z., Strobel S.A., Maggs D.G., Weyer C., and Kolterman O.G. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51 (2002) 636-641
13. Beaumont K., Kenney M.A., Young A.A., and Rink T.J. High affinity amylin binding sites in rat brain. Mol Pharmacol 44 (1993) 493-497
14. Beaumont K., Moore C.X., Pittner R.A., Prickett K.S., Gaeta L.S.L., Rink T.J., and Young A.A. Differential antagonism of amylin's metabolic and vascular actions with amylin receptor antagonists. Can J Physiol Pharmacol 73 (1995) 1025-1029
15. Young A.A., Gedulin B., Gaeta L.S.L., Prickett K.S., Beaumont K., Larson E., and Rink T.J. Selective amylin antagonist suppresses rise in plasma lactate after intravenous glucose in the rat - evidence for a metabolic role of endogenous amylin. FEBS Lett 343 (1994) 237-241
16. Gedulin B., Jodka C., Green D., and Young A. Effect of amylin receptor antagonist, AC187, on labelled glucose absorption and oral glucose tolerance in corpulent LA/N rats. Program and Abstracts, American Diabetes Association 29th Research Symposium and the International Congress on Obesity Satellite Conference, August 25-27, Boston, Mass vol. 40 (1994) (Abstract 45)
17. Gedulin B., Green D., Jodka L., and Young A. Endogenous amylin and gastric emptying in rats: comparison with GLP-1 and CCK-8. Diabetologia 38 (1995) A244
18. Gedulin B., Jodka C., Percy A., and Young A. Neutralizing antibody and the antagonist AC187 may inhibit glucagon secretion in rats. Diabetes 40 suppl 1 (1997) 238A
19. Gedulin B., Percy A., Jodka C., and Young A. Endogenous amylin inhibits glucagon secretion, as demonstrated by studies using neutralizing antibody and the antagonist AC187. Diabet Med 14 suppl 4 (1997) S18
20. Gedulin B., Percy A., Jodka C., and Young A. Studies using neutralizing antibody and the antagonist AC187 reveal that endogenous amylin inhibits glucagon secretion. Diabetologia 40 suppl 1 (1997) A300 [Abstract 1179]
21. Huang H.J., Young A.A., Koda J.E., Tulp O.L., Johnson M.J., and Cooper G.J.S. Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 19 suppl 1 (1992) I-101-I-109
22. Watkins J., Bhavsar S., and Young A.A. Effect of amylin to inhibit food intake in rats can be blocked with the selective amylin receptor antagonist, AC187. Program and Abstracts, 10th International Congress of Endocrinology vol. 419 (1996) (poster P2-57)
23. Beaumont K., Moore C.X., Pittner R.A., Prickett K.S., Gaeta L.S.L., Rink T.J., and Young A.A. Differential antagonism of amylin's metabolic and vascular actions with amylin receptor antagonists. Can J Physiol Pharmacol 73 (1995) 1025-1029
24. 8-37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats. Mol Cell Endocrinol 84 (1992) R1-R5
25. Gedulin B., Larson E., Provost S., and Koda J. The selective amylin antagonist, AC187, enhances the insulin response during intravenous glucose tolerance tests in anesthetized rats. Diabetes 42 suppl 1 (1993) 229A
26. Wang Z.-L., Bennet W.M., Ghatei M.A., Byfield P.G.H., Smith D.M., and Bloom S.R. Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 42 (1993) 330-335
27. Bennet W.M., Beis C.S., Ghatei M.A., Byfield P.G.H., and Bloom S.R. Amylin tonally regulates arginine-stimulated insulin secretion in rats. Diabetologia 37 (1994) 436-438
28. Mather K.J., Paradisi G., Leaming R., Hook G., Steinberg H.O., Fineberg N., Hanley R., and Baron A.D. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev 18 (2002) 118-126
29. Vine W., Smith P., LaChappell R., Rink T.J., and Young A.A. Lactate production from the rat hindlimb is increased after glucose administration and is suppressed by a selective amylin antagonist: evidence for action of endogenous amylin in skeletal muscle. Biochem Biophys Res Commun 216 (1995) 554-559
30. Granqvist L., Permert J., Arnelo U., Adrian T., Westermark P., Smith D.D., and Reidelberger R.D. Effects of AC187, IAPP(8-37) and CGRP(8-37) on IAPP induced anorexia in rats. Digestion 58 suppl 2 (1997) 55
31. Arnelo U., Permert J., Granqvist L., Adrian T., Westermark P., Smith D., and Reidelberger R. Effects of AC187, IAPP 8-37, and CGRP 8-37 on IAPP-induced anorexia in rats. Proc Neurosci Abstr 23 (1997) 102.37 [abstract]
32. Reidelberger R.D., Haver A.C., Arnelo U., Smith D.D., Schaffert C.S., and Permert J. Amylin receptor blockade stimulates food intake in rats. Am J Physiol Regul Integr Comp Physiol 287 (2004) R568-R574
33. Rushing P.A., Hagan M.M., Seeley R.J., Lutz T.A., D'Alessio D.A., Air E.L., and Woods S.C. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142 (2001) 5035-5038
34. Riediger T., Zuend D., Becskei C., and Lutz T.A. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am J Physiol Regul Integr Comp Physiol 286 (2004) R114-R122
35. Unger R.H., Aguilar-Parada E., Muller W.A., and Eisentraut A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49 (1970) 837-848
36. Müller W.A., Faloona G.R., Aguilar-Parada E., and Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283 (1970) 109-115
37. Koda J.E., Fineman M., Rink T.J., Dailey G.E., Muchmore D.B., and Linarelli L.G. Amylin concentrations and glucose control. Lancet 339 (1992) 1179-1180
38. Nyholm B., Orskov L., Hove K.Y., Gravholt C.H., Moller N., Alberti K.G.M.M., Moyses C., Kolterman O.G., and Schmitz O. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48 (1999) 935-941
39. Levetan C., Want L.L., Weyer C., Strobel S.A., Crean J., Wang Y., Maggs D.G., Kolterman O.G., Chandran M., Mudaliar S.R., and Henry R.R. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26 (Jan 2003) 1-8
40. Silvestre R.A., Rodriguez-Gallardo J., Jodka C., Parkes D.G., Pittner R.A., Young A.A., and Marco J. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 280 (2001) E443-E449
41. Sexton P.M., Paxinos G., Kenney M.A., Wookey P.J., and Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62 (1994) 553-567
42. Christopoulos G., Paxinos G., Huang X.F., Beaumont K., Toga A.W., and Sexton P.M. Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 73 (1995) 1037-1041
43. Ganong W.F. Circumventricular organs: definition and role in the regulation of endocrine and autonomic function. Clin Exp Pharmacol Physiol 27 (2000) 422-427
44. Nowak T.V., Roza A.M., Weisbruch J.P., and Brosnan M.R. Accelerated gastric emptying in diabetic rodents: effect of insulin treatment and pancreas transplantation. J Lab Clin Med 123 (1994) 110-116
45. Green G.M., Guan D., Schwartz J.G., and Phillips W.T. Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: role in postprandial hyperglycaemia. Diabetologia 40 (1997) 136-142
46. Young A. Role of amylin in nutrition intake: animal studies. Diabet Med 14 (1997) S14-S18
47. Edwards G.L., Gedulin B.R., Jodka C., Dilts R.P., Miller C.C., and Young A. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin. Neurogastroenterol Motil 10 (1998) 26
48. Lutz T.A. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 6 (2005) 181-189
49. Young A. Inhibition of food intake. Adv Pharmacol 52 (2005) 79-98
50. Riediger T., Schmid H.A., Lutz T., and Simon E. Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. Am J Physiol Regul Integr Comp Physiol 281 (2001) R1833-R1843
51. Hollander P.A., Levy P., Fineman M.S., Maggs D.G., Shen L.Z., Stobel S.A., Weyer C., and Kolterman O.G. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26 (Mar 2003) 784-790
52. Vella A., Lee J.S., Camilleri M., Szarka L.A., Burton D.D., Zinsmeister A.R., Rizza R.A., and Klein P.D. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 14 (2002) 123-131
53. Kong M.F., Stubbs T.A., King P., Macdonald I.A., Lambourne J.E., Blackshaw P.E., Perkins A.C., and Tattersall R.B. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41 (1998) 577-583